Ryoncil's $115M launch year funds the rexlemestrocel-L CLBP Phase 3 bet — the readout determines whether Mesoblast is a commercial platform or a one-product story

Mesoblast is a commercial-stage cell therapy company whose lead approved product treats a bone marrow transplant complication, and whose pipeline depends on a Phase 3 cell injection for chronic low back pain that is not yet approved.

Mesoblast crossed into commercial-stage biotech faster than most peers expected, with Ryoncil generating $115M in its first full year treating pediatric steroid-refractory graft-versus-host disease, a complication of bone marrow transplant. Whether the stock re-rates depends on rexlemestrocel-L, a single intra-discal cell injection for degenerative disc disease chronic low back pain, whose 350-patient Phase 3 readout is the binary. The approval path carries unusual risk: RMAT designation accelerates review, but a single-arm or externally controlled precedent does not apply here — the trial is randomized against sham, so the pivotal question is whether mesenchymal stem cells produce durable pain reduction regulators will accept.